Mohamed Salama,Oscar Arias-Carrión
Mohamed Salama
Experimental models of Parkinson's disease (PD) are of great importance for improving the design of future clinical trials. Various neurotoxic models are available, including 6-hydroxydopamine (6-OHDA), 1-methyl-4-phenyl-1,2,3,6-tetrahydrop...
Optimizing outcomes in multiple sclerosis: consensus guidelines for the diagnosis and treatment of multiple sclerosis in Latin America [0.03%]
优化多发性硬化症的诊疗效果：拉丁美洲多发性硬化症诊断及治疗共识指南
Adriana Carrá,Miguel Ángel Macías-Islas,Alberto Alan Gabbai et al.
Adriana Carrá et al.
Objective: The prevalence of multiple sclerosis (MS) in Latin America varies across different studies but an intermediate risk and increased frequency of the disease have been reported in recent years. The circumstances o...
Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis [0.03%]
评估醋酸格拉默在复发-缓解型多发性硬化治疗中的疗效、安全性和成本效益研究
Aaron Boster,Mary Pat Bartoszek,Colleen O&#x;Connell et al.
Aaron Boster et al.
The current Multiple Sclerosis (MS) therapeutic landscape is rapidly growing. Glatiramer acetate (GA) remains unique given its non-immunosuppressive mechanism of action as well as its superior long-term safety and sustained efficacy data. I...
Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection [0.03%]
褪黑素及其类似物在帕金森病治疗中的潜力：关注睡眠和神经保护作用
Venkatramanujam Srinivasan,Daniel P Cardinali,Uddanapalli S Srinivasan et al.
Venkatramanujam Srinivasan et al.
Sleep disorders constitute major nonmotor features of Parkinson's disease (PD) that have a substantial effect on patients' quality of life and can be related to the progression of the neurodegenerative disease. They can also serve as precli...
The interferon beta therapies for treatment of relapsing-remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combination [0.03%]
评估不同干扰素β制剂用于治疗复发-缓解型多发性硬化症的疗效、安全性和剂量的开放性研究：它们同样有效吗？比较回顾分析
Volker Limmroth,Norman Putzki,Norman J Kachuck
Volker Limmroth
Interferon beta preparations are the most widely used initial therapies prescribed for patients with relapsing-remitting multiple sclerosis. Phase III studies have demonstrated comparable efficacy on clinical measures of disease activity, v...
Intracranial aneurysms: optimized diagnostic tools call for thorough interdisciplinary treatment strategies [0.03%]
颅内动脉瘤：优化的诊断工具呼唤全面的多学科治疗策略
Oliver M Mueller,Marc Schlamann,Daniela Mueller et al.
Oliver M Mueller et al.
Objective: Intracranial aneurysms (IAs) require deliberately selected treatment strategies as they are incrementally found prior to rupture and deleterious subarachnoid haemorrhage (SAH). Multiple and recurrent aneurysms ...
Response of patients with refractory myasthenia gravis to rituximab: a retrospective study [0.03%]
利妥昔单抗治疗难治性重症肌无力患者的疗效回顾性研究
Richard J Nowak,Daniel B Dicapua,Nazlee Zebardast et al.
Richard J Nowak et al.
Introduction: Myasthenia gravis, an autoimmune disorder of neuromuscular transmission, is treated by an array of immunomodulating therapies. A variable response is observed with certain patients being medically refractory...
Wolfgang Grisold,Bruno Giometto,Roberta Vitaliani et al.
Wolfgang Grisold et al.
Paraneoplastic neurological syndromes (PNSs) cover a wide range of diseases and involve both the central nervous system (CNS) and peripheral nervous system. Paraneoplastic encephalitis comprises several diseases such as paraneoplastic cereb...
Multiple sclerosis and chronic cerebrospinal venous insufficiency: a critical review [0.03%]
慢性脑脊髓静脉功能不全与多发性硬化症之批判性评论
Amer M Awad,Ellen Marder,Ron Milo et al.
Amer M Awad et al.
Chronic cerebrospinal venous insufficiency (CCSVI) was recently proposed as a contributing factor in the pathology of multiple sclerosis. This concept has gained remarkable attention, partly because endovascular neurointervention has been s...